Drug Patents owned by Hoffmann La Roche
1. Drug name - BONIVA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7192938 | HOFFMANN LA ROCHE | Method of treatment using bisphosphonic acid |
May, 2023
(7 months from now) | |
| US7410957 | HOFFMANN LA ROCHE | Method of treatment using bisphosphonic acid |
May, 2023
(7 months from now) | |
| US7718634 | HOFFMANN LA ROCHE | Method of treatment using bisphosphonic acid |
May, 2023
(7 months from now) | |
Drugs and Companies using IBANDRONATE SODIUM ingredient
Treatment: Treatment and prevention of osteoporosis in postmenopausal women by once-monthly oral administration of ibandronate sodium monohydrate equivalent to 150mg of ibandronic acid; Treatment and prevention of osteoporosis
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET;ORAL | Discontinued |
| EQ 150MG BASE | TABLET;ORAL | Discontinued |
2. Drug name - VALCYTE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9642911 | HOFFMANN LA ROCHE | Pharmaceutical dosage forms comprising valganciclovir hydrochloride |
Dec, 2027
(5 years from now) | |
| US8889109 | HOFFMANN LA ROCHE | Pharmaceutical dosage forms comprising valganciclovir hydrochloride |
Dec, 2027
(5 years from now) | |
Drugs and Companies using VALGANCICLOVIR HYDROCHLORIDE ingredient
Treatment: NA
Dosage: FOR SOLUTION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 50MG/ML | FOR SOLUTION;ORAL | Prescription |
3. Drug name - ZELBORAF
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8143271 | HOFFMANN LA ROCHE | NA |
Jun, 2026
(3 years from now) | |
| US7504509 | HOFFMANN LA ROCHE | Compounds and methods for development of Ret modulators |
Oct, 2026
(4 years from now) | |
| US7863288 | HOFFMANN LA ROCHE | NA |
Jun, 2029
(6 years from now) | |
| US8741920 | HOFFMANN LA ROCHE | Process for the manufacture of pharmaceutically active compounds |
Jul, 2030
(7 years from now) | |
| CN101223169A | HOFFMANN LA ROCHE | Pyrrolo[2,3-B]Pyridine Derivatives As Protein Kinase Inhibitors |
Jul, 2012
(10 years ago) | |
| CN1925855A | HOFFMANN LA ROCHE | Compounds And Methods For Development Of Ret Modulators |
Dec, 2024
(2 years from now) | |
| CN1925855B | HOFFMANN LA ROCHE | Compounds And Methods For Development Of Ret Modulators |
Dec, 2024
(2 years from now) | |
| CN102603581B | HOFFMANN LA ROCHE | Pyrrolo [2, 3-B] Pyridine Derivate As Protein Kinase Inhibitor |
Jun, 2026
(3 years from now) | |
| CN102206216A | HOFFMANN LA ROCHE | Pyrrolo [2, 3-B] Pyridine Derivate As Protein Kinase Inhibitor |
Jun, 2026
(3 years from now) | |
| CN102603581A | HOFFMANN LA ROCHE | Pyrrolo [2,3-B] Pyridin Derivative As Protein Kinase Inhibitors |
Jun, 2026
(3 years from now) | |
| CN101243084A | HOFFMANN LA ROCHE | Pyrrolo[2,3-B]Pyridine Derivatives As Protein Kinase Inhibitors |
Jun, 2026
(3 years from now) | |
| CN102206216B | HOFFMANN LA ROCHE | Pyrrolo [2, 3-B] Pyridine Derivate As Protein Kinase Inhibitor |
Jun, 2026
(3 years from now) | |
| CN101243084B | HOFFMANN LA ROCHE | Pyrrolo [2, 3-B] Pyridine Derivate As Protein Kinase Inhibitor |
Jun, 2026
(3 years from now) | |
| CN103601725B | HOFFMANN LA ROCHE | Method For Preparing Medicine Active Compound |
Jul, 2030
(7 years from now) | |
| CN102574799A | HOFFMANN LA ROCHE | Process For Manufacture Of Pharmaceutically Active Compounds |
Jul, 2030
(7 years from now) | |
| CN102574799B | HOFFMANN LA ROCHE | Method For Preparation Medicine Active Compound |
Jul, 2030
(7 years from now) | |
| CN103601725A | HOFFMANN LA ROCHE | Method For Preparing Phrmaceutically Active Compounds |
Jul, 2030
(7 years from now) | |
| CN104910150B | HOFFMANN LA ROCHE | Method For Preparing Medicine Active Compound |
Jul, 2030
(7 years from now) | |
| CN104910150A | HOFFMANN LA ROCHE | Method For Preparing Medicine Active Compound |
Jul, 2030
(7 years from now) | |
| IN200704938P2 | HOFFMANN LA ROCHE | Pyrrolo[2,3-B] Pyridine Derivatives As Protein Kinase Inhibitors |
Jun, 2026
(3 years from now) | |
| IN284438B | HOFFMANN LA ROCHE | Pyrrolo[2,3-B] Pyridine Derivatives As Protein Kinase Inhibitors |
Jun, 2026
(3 years from now) | |
| EP1696920A2 | HOFFMANN LA ROCHE | Compounds And Methods For Development Of Ret Modulators |
Dec, 2024
(2 years from now) | |
| EP1696920B1 | HOFFMANN LA ROCHE | Compounds And Methods For Development Of Ret Modulators |
Dec, 2024
(2 years from now) | |
| EP1696920B8 | HOFFMANN LA ROCHE | Compounds And Methods For Development Of Ret Modulators |
Dec, 2024
(2 years from now) | |
| EP1696920A4 | HOFFMANN LA ROCHE | Compounds And Methods For Development Of Ret Modulators |
Dec, 2024
(2 years from now) | |
| EP2395004B1 | HOFFMANN LA ROCHE | Pyrrolo [2,3-B]Pyridine Derivatives As Protein Kinase Inhibitors |
Jun, 2026
(3 years from now) | |
| EP2395004A2 | HOFFMANN LA ROCHE | Pyrrolo [2,3-B]Pyridine Derivatives As Protein Kinase Inhibitors |
Jun, 2026
(3 years from now) | |
| EP2395004A3 | HOFFMANN LA ROCHE | Pyrrolo [2,3-B]Pyridine Derivatives As Protein Kinase Inhibitors |
Jun, 2026
(3 years from now) | |
| EP1893612A1 | HOFFMANN LA ROCHE | Pyrrolo [2, 3-B]Pyridine Derivatives As Protein Kinase Inhibitors |
Feb, 2027
(4 years from now) | |
| EP1893612B1 | HOFFMANN LA ROCHE | Pyrrolo [2, 3-B]Pyridine Derivatives As Protein Kinase Inhibitors |
Feb, 2027
(4 years from now) | |
| EP2462116B1 | HOFFMANN LA ROCHE | Process For The Manufacture Of Pharmaceutically Active Compounds |
Jul, 2030
(7 years from now) | |
| EP2462116A2 | HOFFMANN LA ROCHE | Process For The Manufacture Of Pharmaceutically Active Compounds |
Jul, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8470818 | HOFFMANN LA ROCHE | NA |
Aug, 2026
(3 years from now) | |
| US9447089 | HOFFMANN LA ROCHE | Compositions and uses thereof |
Jun, 2032
(9 years from now) | |
Drugs and Companies using VEMURAFENIB ingredient
Treatment: Zelboraf is indicated for the treatment of patients with erdheim-chester disease with braf v600 mutation; treatment of patients with unresectable or metastatic melanoma with brafv600e mutation as detected by an fda approved test
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 240MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.